Pharmaceuticals: Reimbursement Rates For Popular Meds Under Fire
OIG report claims Medicare is paying higher rates, losing millions.Payments for widely used pharmaceuticals could thin out if the HHS Office of Inspector General gets its way.In a trio of reports released Feb. 2 by the OIG on the pricing of Lupron, ipratropium bromide and albuterol, the agency once again ups the ante on its already longstanding concern over skyrocketing pharmaceutical costs. It wants the Centers for Medicare & Medicaid Services to set "appropriate" payment rates for the drugs after 2004. In 2002, the OIG says Medicare paid $677 million for the cancer drug Lupron - 8...
To read the full article, sign in and subscribe to tci Medicare Compliance & Reimbursement.
Keep pace with evolving Medicare regulations — and onboard your team — with timely analysis of critical updates interpreted in an easy-to-follow, easy-to-apply format. Your subscription to TCI's Medicare Compliance & Reimbursement Alert will equip you to navigate code and guideline changes, CCI edits, and revisions to modifiers, payer policies, the fee schedule, OIG target areas, and more.
Current newsletters added each month
Fully searchable archives - over 4200 articles
ALL years/issues back to 2003 organized by year and issue
Codes mentioned in articles are linked to Code Information pages
Code Information pages link back to related articles
Access to this feature is available in the following products: